Preview Mode Links will not work in preview mode

 

Welcome to the Empowered Patient Podcast with Karen Jagoda.  This show is a window into the latest innovations in digital health and the changing dynamic between doctors and patients.

Topics on the show include

  • the emergence of personalized medicine and breakthroughs in genomics
  • advances in biopharmaceuticals
  • age related diseases and aging in place
  • using big data from wearables and sensors
  • transparency in the medical marketplace
  • challenges for connected health entrepreneurs

The audience includes researchers, medical professionals, patient advocates, entrepreneurs, patients, caregivers, solution providers, students, journalists, and investors.

Mar 4, 2020

David Johnson, CEO and co-founder, GigaGen discusses the company's recombinant intravenous immunoglobulin (IVIG) therapy in development to treat patients with primary immune deficiencies and its potential to overcome limitations of current IVIG plasma-based therapies.  David describes how GigaGen's recombinant IVIG is...


Mar 4, 2020

David Johnson, CEO and co-founder, GigaGen discusses the company's recombinant intravenous immunoglobulin (IVIG) therapy in development to treat patients with primary immune deficiencies and its potential to overcome limitations of current IVIG plasma-based therapies.  David describes how GigaGen's recombinant IVIG is...


Feb 5, 2020

Filippo Petti, CEO, Celyad discusses how the company is broadening precision medicine by developing CAR-T immunotherapies to express a natural killer receptor that can recognize and target multiple ligands expressed in up to 80% of all cancers.  Filippo talks about the value to cancer patients of both personalized...


Feb 5, 2020

Filippo Petti, CEO, Celyad discusses how the company is broadening precision medicine by developing CAR-T immunotherapies to express a natural killer receptor that can recognize and target multiple ligands expressed in up to 80% of all cancers.  Filippo talks about the value to cancer patients of both personalized...


Jan 8, 2020

Dr. Asher Nathan, CEO of NeoTX talks about the company's work developing immunotherapies for a wide range of solid tumors using their proprietary Selective T Cell Redirection (STR) platform.  This technology enables therapies that bind a genetically engineered super antigen to the tumor surface which trigger a native,...